Acquired resistance to targeted drugs and novel therapy to overcome the resistance
نویسندگان
چکیده
منابع مشابه
Resistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملresistance to her2-targeted therapy
production and approval of trastuzumab (herceptin®) for the treatment of metastatic breast cancer (mbc) was a millstone in antibody-based targeted therapy in the cancer treatment. however, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. the majority of patients who benefit from the drug acqui...
متن کاملThe Causes of Resistance to Change and Solutions to Overcome It: A Review of Literature
Introduction: Technological advances as well as science and information explosion necessitate the change in students’ educational needs and in the education system. Researchers consider resistance to change as one of the major causes of the failure of changes. Therefore, the purpose of this review study was to identify the causes of resistance to change and provide solutions to overcome it. Met...
متن کاملanthelmintics resistance; how to overcome it?
many parasitic helminthes of veterinary importance have genetic features that favor development of anthelmintic resistance, this becoming a major worldwide constrain in livestock production. the de-velopment of anthelmintic resistance poses a large threat to future production and welfare of grazing animals. development of variable degrees of resistance among different species of gastrointestina...
متن کاملALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
During the past decade, more than 10 targetable oncogenic driver genes have been validated in non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been reported to be highly effective and well tolerated in these patients. However, resistance to criz...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2017
ISSN: 0923-7534
DOI: 10.1093/annonc/mdx617